Athena Countouriotis's most recent trade in Iovance Biotherapeutics Inc was a trade of 67,546 Deferred Restricted Stock Unit done . Disclosure was reported to the exchange on June 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2025 | 67,546 | 67,546 | - | - | Deferred Restricted Stock Unit | |
| Passage Bio Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 201,857 | 201,857 | - | - | Director Stock Option (right to buy) | |
| Biomarin Pharmaceutical In... | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 6,650 | 13,550 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 49,303 | 49,303 | - | - | Deferred Restricted Stock Unit | |
| Passage Bio Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 47,693 | 47,693 | - | - | Director Stock Option (right to buy) | |
| Biomarin Pharmaceutical In... | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 4,720 | 6,900 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 50,000 | 50,000 | - | - | Deferred Restricted Stock Unit | |
| Biomarin Pharmaceutical In... | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2023 | 2,180 | 2,180 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 51,955 | 51,955 | - | - | Deferred Restricted Stock Unit | |
| Passage Bio Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 24,000 | 24,000 | - | - | Director Stock Option (Right to Buy) | |
| Iovance Biotherapeutics Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 51,204 | 51,204 | - | - | Deferred Restricted Stock Unit | |
| Passage Bio Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 24,000 | 24,000 | - | - | Director Stock Option (Right to Buy) | |
| Iovance Biotherapeutics Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Passage Bio Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 16,918 | 16,918 | - | - | Director Stock Option (Right to Buy) |